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ABSTRACT
Introduction: Effective glycemic control can
reduce the risk of complications and their rela-
ted costs in type 2 diabetes mellitus (T2DM).
However, many patients fail to reach glycemic
targets, often because of adverse effects of
treatment (including hypoglycemia or weight
gain). The present analysis evaluated the
short-term cost-effectiveness of IDegLira versus
continued up-titration of insulin glargine U100
in patients with T2DM failing to achieve gly-
cemic control on basal insulin in the US setting.
Methods: The cost per patient achieving treat-
ment target (cost of control) was assessed for
various single and composite endpoints for the
entire trial population and in patients with
baseline glycated hemoglobin (HbA1c) [8.0%
and HbA1c[9.0%. The proportions of patients
achieving treatment targets were analyzed using
data obtained in the DUAL V study. Costs were
accounted based on published wholesale
acquisition costs.
Results: When assessing the full trial popula-
tion, IDegLira was associated with lower annual
cost of control than continued up-titration of
insulin glargine U100 for patients achieving
HbA1c B6.5% without confirmed hypoglycemia
(by $10,608), HbA1c B6.5% without weight
gain (by $29,215), and HbA1c B6.5% without
confirmed hypoglycemia and weight gain (by
$57,351). A similar pattern was observed when
multifactorial treatment targets were based on
achieving a glycemic target of 7.0%. When only
HbA1c was considered, IDegLira was associated
with a lower cost per patient achieving HbA1c
B6.5% (by $3306) but cost of control was
equivalent for a target of HbA1c \7.0%. In
patients with baseline HbA1c[8.0% and HbA1c
[9.0%, IDegLira was associated with a lower
cost of control for all treatment targets.
Conclusion: The significantly greater clinical
efficacy in terms of bringing patients to treat-
ment targets identified in the DUAL V study
results in lower cost of control values for IDe-
gLira versus continued up-titration of insulin
glargine U100 in the USA. This suggests IDe-
gLira is a cost-effective treatment option in the
USA.
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INTRODUCTION
In the USA, estimates suggest that the total cost
of diagnosed diabetes mellitus in 2012 was
$245 billion, comprised of $176 billion in direct
medical costs and $69 billion in lost produc-
tivity [1]. On a per patient level, estimates have
suggested that a patient with type 2 diabetes
(T2DM) will accrue direct medical costs of
approximately $85,200 over their lifetime, with
costs increasing substantially in patients diag-
nosed at a younger age [2]. The majority of the
total cost (48–64% depending on age at diag-
nosis) is comprised of treatment of diabetes-re-
lated complications. These costs may be
reduced by improving treatment for patients
with T2DM.
Data from a number of large-scale studies
and meta-analyses has shown that improving
glycemic control, as measured by glycated
hemoglobin (HbA1c), can reduce the incidence
of micro- and macrovascular diabetes-related
complications in patients with T2DM [3–9].
Therefore, maintaining glycemic control
despite the progressive nature of the disease has
formed the mainstay of treatment for patients
with T2DM. However, data has also shown that
patients benefit from a multifactorial approach
to treatment where, as well as maintaining tight
glycemic control, treatment aims to minimize
the risk of hypoglycemia, control cardiovascular
risk factors such as blood pressure, serum lipid
levels, and reduce or control body weight
[10, 11]. Controlling these factors may also
result in improved adherence to medications
and therefore improved glycemic control.
Based on this evidence, the American Dia-
betes Association (ADA) has released treatment
guidelines for a number of parameters. The key
target of HbA1c\7% is recommended for most
patients, with a more stringent target of HbA1c
B6.5% if this can be achieved without signifi-
cant hypoglycemia or other adverse effects of
treatment [12]. Recommendations also state
that the effect of medications on body weight
and hypoglycemia risk should be considered
when making treatment decisions [13, 14].
In patients requiring basal insulin, doses can
be titrated to maintain glycemic control. How-
ever, up-titration of basal insulin may result in
weight gain and an increased risk of hypo-
glycemia [15, 16]. IDegLira represents an alter-
native therapy for patients not adequately
controlled on basal insulin. IDegLira is a fixed
ratio combination of insulin degludec and the
glucagon-like peptide-1 (GLP-1) receptor ago-
nist liraglutide. The fixed-ratio combination
was developed to take advantage of the com-
bined effects of a basal insulin and a GLP-1
receptor agonist on glycemic control through
their complementary mechanisms of action.
Treatment with IDegLira has been shown to
result in greater reductions in HbA1c and body
weight, and a lower rate of hypoglycemic events
than insulin glargine U100 [17].
The aim of the present analysis was to eval-
uate, in a simple and transparent analysis, the
short-term cost-effectiveness of IDegLira versus
continued up-titration of insulin glargine U100
in patients with T2DM failing to achieve gly-
cemic control on basal insulin in the US setting.
The analysis assessed the cost per patient
achieving HbA1c-focussed and multifactorial
(capturing weight gain and hypoglycemia)
treatment targets. Insulin glargine U100 was
considered the most appropriate comparator for
the analysis as it is the most commonly pre-
scribed basal insulin in the USA, up-titration of
insulin glargine represents a potential treatment
strategy for patients failing to achieve glycemic
control, and there is published head-to-head
trial evidence comparing the two therapies.
While there are other treatment options for
patients not achieving glycemic control on
basal insulin, there are currently no head-to--
head clinical trials comparing IDegLira with
GLP-1 receptor agonists in combination with
basal insulin (either fixed ratio or free combi-
nations), and the DUAL VII trial comparing
IDegLira with basal-bolus insulin will report in
mid-2017.
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METHODS
Clinical Data
All clinical data used in the analysis were
obtained from the DUAL V trial [17]. DUAL V
was a 26-week, open-label study comparing the
safety and efficacy of IDegLira and continued
up-titration of insulin glargine U100 in patients
with T2DM not achieving glycemic targets on
insulin glargine U100. In total, 557 patients
were randomly allocated to the two treatment
arms in a 1:1 ratio. Confirmed hypoglycemia
was defined as any episode requiring assistance
of another person to actively administer carbo-
hydrate, glucagon, or other resuscitative
actions, or an episode biochemically confirmed
by a plasma glucose value of \3.1 mmol/L
(56 mg/dL), with or without symptoms consis-
tent with hypoglycemia. Three patient popula-
tions were included in the analysis: all patients
included in the DUAL V trial, patients with
HbA1c [8.0% at baseline, and patients with
HbA1c[9.0% at baseline. These three popula-
tions were selected to reflect all patients with
T2DM, and those who are furthest from
achieving recommended treatment targets and
therefore are at the highest risk of developing
diabetes-related complications. In the USA,
55.2% of patients with type 2 diabetes receiving
basal insulin have an HbA1c C8.0%, and 33.1%
have an HbA1c C9.0% [18]. These patient sub-
groups also represent cutoffs applied by the
Diabetes Recognition Program run by the
National Committee for Quality Assurance, and
are therefore highly relevant to healthcare pro-
viders [19]. The proportions of patients achiev-
ing each of the targets in the full trial
population were prespecified secondary end-
points of the study, and analyses in the patient
subgroups were post hoc calculations. IDegLira
was associated with a significantly greater pro-
portion of patients achieving all endpoints in
all three patient populations (Table 1).
Cost Data
Costs were estimated from a healthcare payer
perspective in the USA. Costs captured in the
analysis included the study drug (IDegLira or
insulin glargine U100), needles for subcutaneous
injection, and self-monitoring of blood glucose
(SMBG) testing. No other costs (such as costs of
diabetes-related complications) were included in
the analyses. Doses of IDegLira and insulin
glargine U100 were taken from the DUAL V
study at the end of the trial and used to calculate
daily costs of treatment with each therapy based
on published wholesale acquisition costs
[17, 20]. Costs of SMBG testing were based on an
analysis of insurance claims in the USA and were
inflated using the consumer price index for
medical care [21]. Annual costs were calculated
by multiplying the daily cost by 365.25.
Evaluation of Cost-Effectiveness
The cost per patient achieving target (cost of
control) was assessed for eight endpoints:
HbA1c B6.5%, HbA1c B6.5% without con-
firmed hypoglycemia, HbA1c B6.5% without
weight gain, HbA1c B6.5% without confirmed
hypoglycemia and weight gain, HbA1c \7%,
HbA1c\7% without confirmed hypoglycemia,
HbA1c\7% without weight gain, and HbA1c
\7% without confirmed hypoglycemia and
weight gain. These endpoints were prespecified
in the trial protocol. Outcomes were assessed for
all endpoints in three patient populations: all
patients included in DUAL V, patients with
HbA1c [8.0% at baseline, and patients with
HbA1c[9.0% at baseline.
Cost of control was calculated in an eco-
nomic model developed in Microsoft Excel. The
model calculated the cost per patient achieving
each target with the two interventions by
dividing the annual cost of treatment by the
proportion of patients achieving the target. The
spending required with insulin glargine U100 to
bring one patient to target relative to $1 spent
on IDegLira was calculated by dividing the cost
of control with insulin glargine U100 by the
cost of control with IDegLira. An example cal-
culation for the cost per patient achieving a
treatment target of HbA1c \7% without con-
firmed hypoglycemia and weight gain in the
full DUAL V trial population is shown in
Table 2. The analysis was performed over a
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Table 1 Percentage of patients achieving treatment targets
IDegLira
(%)
Insulin glargine
U100 (%)
P value
Full DUAL V trial population (IDegLira n = 278, insulin glargine U100 n = 279)
HbA1c B6.5% 55.4 30.8 \0.0001
HbA1c B6.5% without conﬁrmed hypoglycemia 41.4 19.0 \0.0001
HbA1c B6.5% without weight gain 41.7 12.5 \0.0001
HbA1c B6.5% without conﬁrmed hypoglycemia and weight gain 31.7 7.5 \0.0001
HbA1c\7.0% 71.6 47.0 \0.0001
HbA1c\7.0% without conﬁrmed hypoglycemia 54.3 29.4 \0.0001
HbA1c\7.0% without weight gain 50.0 19.7 \0.0001
HbA1c\7.0% without conﬁrmed hypoglycemia and weight gain 38.8 12.2 \0.0001
Patients with HbA1c[8.0% at baselineb (IDegLira n = 168, insulin glargine U100 n = 155)
HbA1c B6.5% 48.8 20.0 \0.0001
HbA1c B6.5% without conﬁrmed hypoglycemia 37.5 12.3 \0.0001
HbA1c B6.5% without weight gain 35.7 5.8 \0.0001
HbA1c B6.5% without conﬁrmed hypoglycemia and weight gain 27.4 3.2 \0.0001
HbA1c\7.0% 64.3 34.2 \0.0001
HbA1c\7.0% without conﬁrmed hypoglycemia 50.6 20.0 \0.0001
HbA1c\7.0% without weight gain 44.0 11.0 \0.0001
HbA1c\7.0% without conﬁrmed hypoglycemia and weight gain 35.1 6.5 \0.0001
Patients with HbA1c[9.0% at baselineb (IDegLira n = 71, insulin glargine U100 n = 52)
HbA1c B6.5% 38.0 13.5 0.0052
HbA1c B6.5% without conﬁrmed hypoglycemia 26.8 5.8 0.0087
HbA1c B6.5% without weight gain 25.4 0.0 Not deﬁneda
HbA1c B6.5% without conﬁrmed hypoglycemia and weight gain 18.3 0.0 Not deﬁneda
HbA1c\7.0% 56.3 23.1 0.0006
HbA1c\7.0% without conﬁrmed hypoglycemia 42.3 11.5 0.0013
HbA1c\7.0% without weight gain 33.8 1.9 0.0026
HbA1c\7.0% without conﬁrmed hypoglycemia and weight gain 26.8 1.9 0.0077
Statistical signiﬁcance was assessed at the 95% conﬁdence level
HbA1c glycated hemoglobin
a No patients in the insulin glargine U100 arm achieved the treatment target and therefore a p value could not be deﬁned
b Post hoc analysis
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1-year time horizon, and therefore no dis-
counting was applied. A 1-year time horizon
was chosen as it represents a highly relevant
period to a healthcare payer. The present anal-
ysis is intended to complement conventional
long-term analyses, and a long-term analysis
based on DUAL V will be published separately.
Compliance with Ethics
This article does not contain any new studies
with human or animal subjects performed by
any of the authors.
RESULTS
Annual Cost Outcomes
Annual treatment costs were higher for patients
receiving IDegLira than for patients receiving
insulin glargine U100 because of the higher
acquisition costs of IDegLira (Table 3). The
annual cost difference was smaller when
patients with HbA1c [8.0% at baseline and
HbA1c[9.0% at baseline were considered. This
was a result of doses being higher in both arms
in these subgroups, but increases in insulin
glargine U100 doses were larger than increases
in IDegLira doses. Needle costs showed only
small variation between the two treatment arms
in all three patient groups, and costs of SMBG
testing were equal.
Number Needed to Treat
IDegLira was consistently associated with a
lower number needed to treat (NNT) to bring
one patient to target for all endpoints and in all
patient populations included in the analysis
(Table 4). Differences were greatest in all three
patient populations for multifactorial treatment
Table 2 Example cost of control calculation for a treatment target of HbA1c\7% without conﬁrmed hypoglycemia and
weight gain in the full DUAL V trial population
IDegLira Insulin glargine U100 Interpretation
Annual drug cost ($) 10,280 6734
Drug cost index 10,280/6734 = 1.5 6734/6734 = 1.0 IDegLira is 50% more costly than insulin
glargine U100 on an annual per patient
basis
Drug efﬁcacy (% of
patients achieving
control)
38.8 12.2
Drug efﬁcacy index 38.8/12.2 = 3.2 12.2/12.2 = 1.0 IDegLira is over 3 times more effective in
terms of bringing patients to target versus
insulin glargine U100
Cost per patient
achieving control ($)
10,280/
38.8 9 100 = 36,495
6734/
12.2 9 100 = 55,193
Cost of control index 36,495/55,193 = 0.5 55,193/55,193 = 1.0 IDegLira costs approximately half of the
amount of insulin glargine U100 to
achieve a similar outcome
Amount spent to achieve
target relative to $1
spent on IDegLira
36,495/36,495 = 1.0 55,193/36,495 = 2.08 For every $1 spent on IDegLira, $2.08
must be spent on insulin glargine U100
to bring 1 patient to control
$, 2015 US dollars
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targets which included avoidance of confirmed
hypoglycemia and weight/or gain, and when
subgroups of patients with higher HbA1c values
at baseline were considered.
Cost of Control
In the full DUAL V trial population (Fig. 1), the
annual cost per patient achieving a target of
HbA1c B6.5% was lower with IDegLira than with
continued up-titration of insulin glargine U100
($18,556 versus $21,862) but the annual cost per
patient achieving target of HbA1c \7.0% was
equivalent in the two arms ($14,358 versus
$14,327). However, when confirmed hypo-
glycemia and/or no weight gain were included in
the targets, IDegLira was associated with a lower
annual cost of control for all endpoints. The
annual costs per patient achieving targets of
HbA1c B6.5% without confirmed hypoglycemia,
HbA1c B6.5% without weight gain, and HbA1c
B6.5% without confirmed hypoglycemia and
weight gain were $10,608, $29,215, and $57,351
lower with IDegLira than with continued up-ti-
tration of insulin glargine U100, respectively. To
bring one patient to a target of HbA1c B6.5% or
HbA1c B7.0% without confirmed hypoglycemia
and weight gain with continued up-titration of
insulin glargine U100 required spending of $2.77
or $2.08, respectively, for every $1 spent on
IDegLira.
Table 3 Cost outcomes
IDegLira ($) Insulin glargine U100 ($)
Full DUAL V trial population
Annual cost of IDegLira 9516 –
Annual cost of insulin glargine U100 – 5991
Annual cost of needles 167 146
Annual cost of SMBG testing 597 597
Total annual cost 10,280 6734
Patients with HbA1c[8.0% at baseline
Annual cost of IDegLira 9631 –
Annual cost of insulin glargine U100 – 6580
Annual cost of needles 167 146
Annual cost of SMBG test strips 597 597
Total annual cost 10,395 7323
Patients with HbA1c[9.0% at baseline
Annual cost of IDegLira 9784 –
Annual cost of insulin glargine U100 – 6932
Annual cost of needles 167 146
Annual cost of SMBG testing 597 597
Total annual cost 10,549 7675
Columns may not sum exactly due to rounding
$, 2015 US dollars
SMBG self-monitoring of blood glucose
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Table 4 Number needed to treat to bring one patient to target
IDegLira Insulin
glargine U100
Absolute
difference
Full DUAL V population
HbA1c B6.5% 1.8 3.2 -1.4
HbA1c B6.5% without conﬁrmed hypoglycemia 2.4 5.3 -2.8
HbA1c B6.5% without weight gain 2.4 8.0 -5.6
HbA1c B6.5% without conﬁrmed
hypoglycemia and weight gain
3.2 13.3 -10.2
HbA1c\7.0% 1.4 2.1 -0.7
HbA1c\7.0% without conﬁrmed hypoglycemia 1.8 3.4 -1.6
HbA1c\7.0% without weight gain 2.0 5.1 -3.1
HbA1c\7.0% without conﬁrmed
hypoglycemia and weight gain
2.6 8.2 -5.6
Patients with HbA1c[8.0% at baselineb
HbA1c B6.5% 2.0 5.0 -3.0
HbA1c B6.5% without conﬁrmed hypoglycemia 2.7 8.1 -5.5
HbA1c B6.5% without weight gain 2.8 17.2 -14.4
HbA1c B6.5% without conﬁrmed hypoglycemia
and weight gain
3.6 31.3 -27.6
HbA1c\7.0% 1.6 2.9 -1.4
HbA1c\7.0% without conﬁrmed hypoglycemia 2.0 5.0 -3.0
Patients with HbA1c[9.0% at baselineb
HbA1c B6.5% 2.6 7.4 -4.8
HbA1c B6.5% without conﬁrmed hypoglycemia 3.7 17.2 -13.5
HbA1c B6.5% without weight gain 3.9 Cannot be calculateda Cannot be calculateda
HbA1c B6.5% without conﬁrmed
hypoglycemia and weight gain
5.5 Cannot be calculateda Cannot be calculateda
HbA1c\7.0% 1.8 4.3 -2.6
HbA1c\7.0% without conﬁrmed hypoglycemia 2.4 8.7 -6.3
HbA1c\7.0% without weight gain 3.0 52.6 -49.7
HbA1c\7.0% without conﬁrmed
hypoglycemia and weight gain
3.7 52.6 -48.9
Rows may not sum exactly due to rounding
HbA1c glycated hemoglobin
a Number needed to treat values cannot be calculated as nopatients in the insulin glargineU100 arm achieved the treatment target
b Post hoc analysis
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Cost of control values were higher for all
treatment targets in both treatment arms in
patients with HbA1c[8.0% at baseline than in
the full DUAL V trial population (Fig. 2). IDe-
gLira was associated with a lower cost per
patient achieving control for all treatment tar-
gets, both when only HbA1c was considered
and for multifactorial targets. Differences
between the treatment arms were largest when
avoidance of weight gain and confirmed hypo-
glycemia were captured in the analysis. Bring-
ing one patient to a target of HbA1c \7.0%
without confirmed hypoglycemia and weight
gain required annual spending of $29,616 with
IDegLira and $112,663 with continued up-ti-
tration of insulin glargine U100, a difference of
$83,047 per year.
When patients with HbA1c [9.0% at base-
line were considered, IDegLira was associated
with a lower cost per patient achieving glycemic
targets of HbA1c B6.5% and HbA1c \7.0%
(Fig. 3). To bring one patient to HbA1c B6.5%
or HbA1c\7.0% with continued up-titration of
insulin glargine U100 required spending of
$2.05 and $1.77, respectively, for $1 spent on
IDegLira. IDegLira was also associated with
lower costs of control values when multifacto-
rial treatment targets were considered. No
patients in the continued up-titration of insulin
glargine U100 arm achieved the targets of
HbA1c B6.5% without confirmed hypoglycemia
and weight gain or HbA1c B6.5% without
confirmed hypoglycemia and weight gain, with
costs of control for IDegLira of $41,530 and
$57,642, respectively, for these targets. The
annual cost per patient achieving targets of
HbA1c \7.0% with no confirmed hypo-
glycemia, HbA1c \7.0% with no weight gain,
and HbA1c\7.0% with no weight gain and no
confirmed hypoglycemia were $41,799,
$372,723, and $364,571 lower with IDegLira
than with continued up-titration of insulin
glargine U100, respectively.
DISCUSSION
On the basis of data from the DUAL V trial,
IDegLira is more efficacious than up titration of
insulin glargine U100 in terms of bringing
patients to treatment targets, both HbA1c-fo-
cused and multifactorial. While IDegLira was
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Fig. 1 Cost of control: full DUAL V population. $, 2015 US dollars; HbA1c, glycated hemoglobin
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associated with increased treatment costs, the
cost of control was lower than continued
up-titration of insulin glargine U100 for the
majority of endpoints included in the analysis.
Differences in the cost of control values were
greatest when treatment targets including
hypoglycemia and/or weight gain were consid-
ered. This reflects the wide-ranging benefits of
HbA1c  6.5% 
HbA1c  6.5% 
without 
confirmed 
hypoglycemia 
HbA1c  6.5% 
without weight 
gain 
HbA1c  6.5%, 
without 
confirmed 
hypoglycemia 
and  weight gain 
HbA1c < 7.0%
HbA1c < 7.0%
without
confirmed
hypoglycemia
HbA1c < 7.0%
without weight
gain
HbA1c < 7.0%,
without
confirmed
hypoglycemia
and  weight gain
IDegLira
Insulin Glargine U100
21,302 27,721 29,119 37,939 16,167 20,544 23,626 29,616
36,615 59,537 1,26,260 2,28,846 21,412 36,615 66,573 1,12,663
0
50,000
1,00,000
1,50,000
2,00,000
2,50,000
C
os
t o
f c
on
tro
l (
$)
 
Fig. 2 Cost of control: patients with HbA1c[8.0% at baseline. $, 2015 US dollars; HbA1c, glycated hemoglobin
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Fig. 3 Cost of control: patients with HbA1c [9.0% at
baseline. $, 2015 US dollars; HbA1c, glycated hemoglobin.
*Cost of control values cannot be calculated in the insulin
glargine U100 arm for HbA1c B6.5% without weight gain
and HbA1c B6.5% without conﬁrmed hypoglycemia and
weight gain, as no patients in the insulin glargine U100
arm achieved these treatment targets
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treatment with IDegLira, targeting not only
glycemic control but other risk factors which
may reduce the long-term risk of diabetes-re-
lated complications and associated costs.
IDegLira also showed significantly greater
efficacy and lower cost of control in patients
with higher HbA1c values at baseline. This was
particularly notable in patients with HbA1c
[9.0% at baseline, where no patients achieved
the treatment targets with continued up-titra-
tion of insulin glargine U100 for the composite
endpoints of HbA1c B6.5% without weight gain
and HbA1c B6.5% without confirmed hypo-
glycemia and weight gain. This may be a par-
ticularly important characteristic of treatment
with IDegLira, with the ability to bring patients
with poor glycemic control to recommended
treatment targets [12–14]. This could allow care
to improve across a wide range of patients with
T2DM and increase the proportion of patients
achieving recognized quality control measures
at a lower cost than with alternative interven-
tions. The treatment characteristics of IDegLira,
using the complementary mechanisms of
action of a basal insulin and a GLP-1 receptor
agonist in a single once-daily injection, result in
the ability to achieve glycemic control whilst
mitigating the risk of hypoglycemia and weight
gain, and this improved efficacy offsets
increased treatment costs to result in a lower
cost of control.
An advantage of the present analysis is the
ability to assess the short-term cost-effective-
ness of IDegLira versus continued up-titration
of insulin glargine U100 in a simple and
transparent manner. Therefore the analysis
can be easily replicated and updated when
acquisition costs of interventions change or
when new clinical data (such as new clinical
trials, meta-analyses, or additional post hoc
analyses) become available. The analysis does
not use long-term projections of clinical and
cost outcomes, as are often used in assess-
ments of cost-effectiveness of interventions
for T2DM [22]. As a result of the absence of
long-term data, such analyses require
assumptions around changes in risk factors
over time (such as HbA1c, systolic blood
pressure, serum lipids, and body weight) and
durability of treatment. Furthermore, there
may be uncertainty around risk equations
used to predict how changes in surrogate
outcomes affect the likelihood of end-stage
complications [23]. As a result, such analyses
are often complex and may be difficult for
some audiences to interpret. The analyses
described above used an alternative approach,
assessing the cost per patient achieving treat-
ment targets based on guidelines released by
the American Diabetes Association [12–14].
Analyses using a similar approach to the pre-
sent analysis have been previously conducted
and published in the USA and Canada
[24–26].
One of the key limitations of the analysis is
that it does not offer a willingness to pay con-
text, as the questions of how much a healthcare
payer is willing to pay per patient achieving
control is an open one. Therefore it is not pos-
sible to generalize across analyses or therapeutic
areas, which is a key advantage of the more
conventional approach to cost-effectiveness
analysis in which the cost per quality-adjusted
life year (QALY) gained is calculated. As such,
the approach described is not intended to
replace conventional, long-term modeling, but
provide complementary information to assist
decision-makers with a more short-term
horizon.
A further limitation of the analysis may be
that acute complications, other than hypo-
glycemia, were not captured in the clinical
responder endpoints. In the DUAL V study,
patients receiving IDegLira were at an increased
risk of nausea (9.4% versus 1.1%), diarrhea
(7.2% versus 2.5%), and vomiting (5.0% versus
1.8%), compared with patients receiving insulin
glargine U100. These acute events may affect
adherence to medications and therefore both
clinical effectiveness and costs may be altered.
Further post hoc analysis may allow these
adverse events to be captured in additional
composite endpoints and therefore to be
reflected in the cost of control calculations. The
most frequent adverse event in the DUAL V trial
was hypoglycemia. The cost of hypoglycemia
was not included in the present analysis, as the
higher rate in the insulin glargine U100 arm
would have resulted in a greater increase in
costs with insulin glargine U100 compared with
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IDegLira. This conservative assumption was
chosen to avoid biasing the analysis in favor of
IDegLira.
In addition, not all possible treatments a
patient not achieving glycemic control on basal
insulin may receive have been included in the
present analysis. Other treatment intensifica-
tion options include basal-bolus insulin and
addition of liraglutide [14]. To date, there is no
direct head-to-head trial evidence comparing
IDegLira with these treatment options,
although the DUAL VII study comparing IDe-
gLira with basal-bolus insulin will report in
mid-2017.
The study also assumes 100% adherence to
all medications included in the analysis, and
this has the potential to lead to an overestima-
tion of pharmacy costs and therefore costs of
control. In the absence of real-life data on
adherence for IDegLira and insulin glargine
U100, and the unknown impact of non-adher-
ence on clinical outcomes, it would have been
very difficult to incorporate adherence into this
analysis. A final limitation may be the use of
wholesale acquisition costs. This may also have
led to an overestimate of cost of control values,
as potential contracting and rebate structures
between the healthcare plans and manufactur-
ers were not captured.
CONCLUSIONS
The present analysis assessed the short-term
cost-effectiveness of IDegLira versus continued
up-titration of insulin glargine U100 in patients
failing to achieve glycemic targets on basal
insulin alone. The greater clinical efficacy in
terms of bringing patients to treatment targets
identified in the DUAL V study results in lower
cost of control values for IDegLira versus con-
tinued up-titration of insulin glargine U100
from a healthcare payer perspective in the USA.
Cost-effectiveness benefits were largest when
treatment targets including hypoglycemia and/
or weight gain and patients with higher HbA1c
levels were considered. These findings suggest
that IDegLira is a cost-effective treatment
option versus continued up-titration of insulin
glargine U100 in the USA.
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